Depatuxizumab mafodotin

N/A

Report date: 2024/02/05 14:07:49

Base Information

Drug NameDepatuxizumab mafodotin
Drug Alias NameDepatux-MABT-414ABT-414/806
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > MMAF payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsEpidermal growth factor receptor erbB1 antagonists
TargetsEpidermal growth factor receptor erbB1Tubulin
Therapy Area/IndicationsCarcinoma, Squamous CellGliosarcomaGlioblastoma +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[32] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbott LaboratoriesAbbvie Inc
Inactive CompaniesBsp Pharmaceuticals SrlAbbvie Pharmaceutical Trading（Shanghai）Co Ltd
Active IndicationsGliosarcomaGlioblastoma
Inactive IndicationsCarcinoma, Squamous CellGlioma

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG